These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 38976688)
1. Preclinical safety assessment of modified gamma globin lentiviral vector-mediated autologous hematopoietic stem cell gene therapy for hemoglobinopathies. Shadid M; Shrestha A; Malik P PLoS One; 2024; 19(7):e0306719. PubMed ID: 38976688 [TBL] [Abstract][Full Text] [Related]
2. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. Pestina TI; Hargrove PW; Jay D; Gray JT; Boyd KM; Persons DA Mol Ther; 2009 Feb; 17(2):245-52. PubMed ID: 19050697 [TBL] [Abstract][Full Text] [Related]
3. Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia. Zhao HF; Abraham A; Kim YS; Wang YD; Pestina T; Zhan J; Humphries K; Nienhuis AW; Persons DA Mol Ther; 2017 Mar; 25(3):593-605. PubMed ID: 28190779 [TBL] [Abstract][Full Text] [Related]
4. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene. Zhao H; Pestina TI; Nasimuzzaman M; Mehta P; Hargrove PW; Persons DA Blood; 2009 Jun; 113(23):5747-56. PubMed ID: 19365082 [TBL] [Abstract][Full Text] [Related]
5. Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells. Urbinati F; Hargrove PW; Geiger S; Romero Z; Wherley J; Kaufman ML; Hollis RP; Chambers CB; Persons DA; Kohn DB; Wilber A Exp Hematol; 2015 May; 43(5):346-351. PubMed ID: 25681747 [TBL] [Abstract][Full Text] [Related]
6. Gene Therapy for beta-thalassemia. Malik P; Arumugam PI Hematology Am Soc Hematol Educ Program; 2005; ():45-50. PubMed ID: 16304358 [TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of lentiviral gene transfer approaches designed to promote fetal hemoglobin production for the treatment of β-hemoglobinopathies. Daniel-Moreno A; Lamsfus-Calle A; Wilber A; Chambers CB; Johnston I; Antony JS; Epting T; Handgretinger R; Mezger M Blood Cells Mol Dis; 2020 Sep; 84():102456. PubMed ID: 32498026 [TBL] [Abstract][Full Text] [Related]
8. Gene Therapy Approaches to Hemoglobinopathies. Ferrari G; Cavazzana M; Mavilio F Hematol Oncol Clin North Am; 2017 Oct; 31(5):835-852. PubMed ID: 28895851 [TBL] [Abstract][Full Text] [Related]
9. Ex Vivo Selection of Transduced Hematopoietic Stem Cells for Gene Therapy of β-Hemoglobinopathies. Bhukhai K; de Dreuzy E; Giorgi M; Colomb C; Negre O; Denaro M; Gillet-Legrand B; Cheuzeville J; Paulard A; Trebeden-Negre H; Borwornpinyo S; Sii-Felice K; Maouche L; Down JD; Leboulch P; Payen E Mol Ther; 2018 Feb; 26(2):480-495. PubMed ID: 29221807 [TBL] [Abstract][Full Text] [Related]
10. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders. Persons DA Hematology Am Soc Hematol Educ Program; 2009; ():690-7. PubMed ID: 20008255 [TBL] [Abstract][Full Text] [Related]
11. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Perumbeti A; Higashimoto T; Urbinati F; Franco R; Meiselman HJ; Witte D; Malik P Blood; 2009 Aug; 114(6):1174-85. PubMed ID: 19474450 [TBL] [Abstract][Full Text] [Related]
12. Gene Therapy for Sickle Cell Disease: A Lentiviral Vector Comparison Study. Urbinati F; Campo Fernandez B; Masiuk KE; Poletti V; Hollis RP; Koziol C; Kaufman ML; Brown D; Mavilio F; Kohn DB Hum Gene Ther; 2018 Oct; 29(10):1153-1166. PubMed ID: 30198339 [TBL] [Abstract][Full Text] [Related]
13. The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number. Persons DA; Hargrove PW; Allay ER; Hanawa H; Nienhuis AW Blood; 2003 Mar; 101(6):2175-83. PubMed ID: 12411297 [TBL] [Abstract][Full Text] [Related]
14. The new self-inactivating lentiviral vector for thalassemia gene therapy combining two HPFH activating elements corrects human thalassemic hematopoietic stem cells. Papanikolaou E; Georgomanoli M; Stamateris E; Panetsos F; Karagiorga M; Tsaftaridis P; Graphakos S; Anagnou NP Hum Gene Ther; 2012 Jan; 23(1):15-31. PubMed ID: 21875313 [TBL] [Abstract][Full Text] [Related]
15. Gene Therapy for Hemoglobinopathies. Cavazzana M; Mavilio F Hum Gene Ther; 2018 Oct; 29(10):1106-1113. PubMed ID: 30200783 [TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease. Negre O; Bartholomae C; Beuzard Y; Cavazzana M; Christiansen L; Courne C; Deichmann A; Denaro M; de Dreuzy E; Finer M; Fronza R; Gillet-Legrand B; Joubert C; Kutner R; Leboulch P; Maouche L; Paulard A; Pierciey FJ; Rothe M; Ryu B; Schmidt M; von Kalle C; Payen E; Veres G Curr Gene Ther; 2015; 15(1):64-81. PubMed ID: 25429463 [TBL] [Abstract][Full Text] [Related]
17. Advances in stem cell transplantation and gene therapy in the β-hemoglobinopathies. Payen E; Leboulch P Hematology Am Soc Hematol Educ Program; 2012; 2012():276-83. PubMed ID: 23233592 [TBL] [Abstract][Full Text] [Related]
18. Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials. Segura EER; Ayoub PG; Hart KL; Kohn DB Viruses; 2023 Mar; 15(3):. PubMed ID: 36992422 [TBL] [Abstract][Full Text] [Related]